Atika Capital Management’s Abivax ABVX Stock Holding History

Atika Capital Management’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.6M	Sell	27,000 -1,800	-6%	-$204K	0.24%	67
2026 Q1	$3.21M	Sell	28,800 -26,200	-48%	-$3.1M	0.4%	54
2025 Q4	$7.42M	Sell	55,000 -14,000	-20%	-$1.53M	0.78%	42
2025 Q3	$5.86M	Buy	+69,000	New	+$4.23M	0.47%	52
2025 Q1	–	Sell	-103,929	Closed	-$761K	–	64
2024 Q4	$761K	Sell	103,929 -9,702	-9%	-$89.3K	0.08%	81
2024 Q3	$1.31M	Sell	113,631 -57,006	-33%	-$683K	0.13%	83
2024 Q2	$2.26M	Buy	170,637 +120,644	+241%	+$1.73M	0.22%	81
2024 Q1	$715K	Buy	+49,993	New	+$645K	0.07%	88

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atika Capital Management's ABVX Position: Q2 2026 in Review

Atika Capital Management reduced its Abivax (ABVX) stake by 6.3% in Q2 2026, selling an estimated $204K and leaving 27,000 shares worth $3.6M. The position accounts for 0.24% of the portfolio, ranked #67.

Atika Capital Management first reported a position in ABVX in Q1 2024 and has held it in 8 quarters since. The position peaked at $7.42M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Atika Capital Management held 27,000 shares of Abivax worth $3.6M as of Q2 2026.
Atika Capital Management sold 1,800 Abivax shares in Q2 2026, an estimated $204K.
Abivax made up 0.24% of Atika Capital Management's portfolio in Q2 2026, its #67 holding.
Atika Capital Management first reported a position in Abivax in Q1 2024 and has held it in 8 quarters since.
Atika Capital Management's Abivax position peaked at $7.42M in Q4 2025.
302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.